Fri, Jul 25, 2014, 3:11 AM EDT - U.S. Markets open in 6 hrs 19 mins

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • marinolman11 marinolman11 Jan 12, 2014 4:15 PM Flag

    The forgotten Foretinib or Xl 880

    Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
    Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
    Author information

    Dana-Farber Cancer Institute, Boston, MA, USA.
    Abstract
    PURPOSE:
    Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC.
    PATIENTS AND METHODS:
    Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR).
    RESULTS:
    Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli.
    CONCLUSION:
    Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.
    Comment in

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
EXEL
4.21+0.43(+11.38%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Amazon.com Inc.
NasdaqGSThu, Jul 24, 2014 4:00 PM EDT
Burger King Worldwide, Inc.
NYSEThu, Jul 24, 2014 4:01 PM EDT
Puma Biotechnology, Inc.
NYSEThu, Jul 24, 2014 4:02 PM EDT